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Abstract
Background: GPIIb/IIIa inhibitors abciximab and eptifibatide have been shown to inhibit platelet
aggregation in ischemic heart disease. Our aim was to test the efficacy of abiciximab (Reo Pro) or
eptifibatide (Integrilin) alone or in combination with plasminogen activator (t-PA) in an
experimental model of ischemia reperfusion (I/R) in hamster cheek pouch microcirculation
visualized by fluorescence microscopy. Hamsters were treated with saline, or abiciximab or
eptifibatide or these drugs combined with t-PA infused intravenously 10 minutes before ischemia
and through reperfusion. We measured the microvessel diameter changes, the arteriolar red blood
cell (RBC) velocity, the increase in permeability, the perfused capillary length (PCL), and the platelet
and leukocyte adhesion on microvessels.
Results: I/R elicited large increases in the platelet and leukocyte adhesion and a decrease in
microvascular perfusion. These responses were significantly attenuated by abiciximab or
eptifibatide (PCL:70 and 65% at 5–10 mins of reperfusion and 85 and 87% at 30 mins of reperfusion,
respectively, p < 0.001) while t-PA combined with abiciximab or eptifibatide, was more effective
and microvascular perfusion recovered immediately after postischemic reperfusion.
Conclusions: Platelets are crucial in I/R injury, as shown by the treatment with abicixmab or
eptifibatide, which decreased platelet aggregation in microvessels, and also decreased leukocyte
adhesion in venules. Arterial vasoconstriction, decreased arterial RBC velocity and alterations in
the endothelial barrier with increased permeability delayed the complete restoration of blood flow,
while t-PA combined with inhibition of platelet aggregation speeded up the capillary perfusion after
reperfusion.
Background
A role for platelets in the pathogenesis of I/R is supported
by reports describing a beneficial effect of platelet deple-
tion in the no-reflow phenomenon in different experi-
mental models of I/R [1–3]. Platelets are a major
constituent of newly formed thrombi and contribute sig-
nificantly to vaso-occlusive disease in I/R-induced injury
because the platelet-endothelial interactions are not con-
fined to postcapillary venules but have been also observed
in arterioles during I/R [4].
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Inhibitors of the platelet glycoprotein gpIIb/IIIa have
been designed, which interfere with the ability of these re-
ceptors to bind fibrinogen and thus to form platelet aggre-
gates. These are a chimeric monoclonal antibody (c7E3
Fab), Reo Pro or abciximab [5–9] and a cyclic heptapep-
tide, Integrilin or eptifibatide [10–12] containing a KGD
sequence developed as a high affinity mimic of the fibrin-
ogen RGD sequence, which binds to the gp IIb-IIIa recep-
tor. They have been shown to be specific for inhibition of
platelet aggregation (and possibly adhesion) in human
ischemic heart disease [10,13,14]. However, there have
been different studies on the effects of these compounds
in vitro and in humans, but the efficacy at the level of the
microvessels, which comprise this network range in size
from 5 to 150 µm, during I/R has not been reported.
Epidemiological studies have shown complete restoration
of blood flow with plasma tissue plasminogen activator
(t-PA) levels but the incidence of microvascular reocclu-
sion, caused by arterial thrombosis, is high in patients
[13,15,16]. t-PA, released from endothelial cells, is a ma-
jor activator of fibrinolysis and has a major role in platelet
adhesion to damaged vessels [17]. A combination reper-
fusion regimen that includes abciximab and a reduced
dose of a thrombolytic agent, followed by an early adjunc-
tive percutaneous coronary intervention, was associated
with greater ST-segment resolution [18]. Combined accel-
erated t-PA and eptifibatide in human acute myocardial
infarction showed that the restoration of perfusion can be
enhanced when eptifibatide is associated with other drugs
such as alteplase, aspirin or intravenous heparin factors
that can protect the endothelium [19]. Injury to endothe-
lial cells may suppress production of prostacyclin and
promote production of tromboxaneA2 in the vessel wall
thus causing platelets to become adherent to damaged
vessels.
Previously, we showed that the removal of leukocytes
(leukopenia) was protective against I/R injury, only when
it was in combination with t-PA treatment [20], thus
showing evidence that leukocytes and t-PA play a central
role in thrombosis and are involved in the fibrinolytic
processes.
Although abiciximab and eptifibatide exhibit significant
benefits in treating I/R injury, it is unclear whether their
therapeutic properties are localized in the inhibition of
platelet aggregation alone or in the protection of endothe-
lial cells with the inhibition of leukocyte adhesion mole-
cules and endothelium-platelet or platelet-leukocyte
interactions.
The first aim of our study was to determine the efficacy of
abciximab or eptifibatide to attenuate leukocyte adhesion
and to restore blood flow after I/R-induced injury in the
hamster cheek pouch microcirculation. The second aim
was to test whether t-PA combined with gpIIb-IIIa antag-
onists would increase microvascular perfusion after I/R.
The adherent platelets and leukocytes in microvessels,
capillary perfusion (capillary segments perfused by red
blood cells, perfused capillary length, PCL), increased per-
meability, and arteriolar and venular RBC velocity were
investigated by fluorescence microscopy.
Results
MAP and heart rate were 90 ± 7 mm Hg and 280 ± 10
beats/min during baseline conditions and they did not
change significantly after I/R. t-PA, abicimax and eptifi-
batide did not affect either MAP or heart rate significantly.
Changes in arteriolar diameter and RBC velocity
The changes in the diameter of arterioles (baseline: 55 ± 7
µm, n = 15) measured after 30 min of reperfusion are
shown in Fig. 1. In the I/R group the diameter of arterioles
decreased significantly after reperfusion compared with
baseline (-45% vs. baseline, p < 0.05) whereas the venules
dilated slightly. The values in tPA group were not signifi-
cantly different compared with I/R group during baseline
and reperfusion (tPA: -36% vs. baseline, p < 0.05).
In tAB and tEF groups there was a significant increase in
arteriolar diameter compared with I/R whereas in the
groups treated with t-Pa combined with gpIIa/IIIb inhibi-
tors, diameters maintained or increased its baseline value
at the end of the observation period (tAB: +12% and tEF:
+ 15% vs. the AB and EF groups, respectively p < 0.05).
There was not a significant difference in baseline RBC ve-
locity in I/R and tPA groups. Just after the ischemic period
a significant decrease in RBC velocity was observed in
both groups and during the subsequent period of reper-
fusion (1.98 ± 0.35 mm/s at baseline, p < 0.05) (Fig. 2).
In AB and EF groups RBC velocity increased significantly
in arterioles during reperfusion in comparison with I/R (p
< 0.05, Figs. 1,2) whereas it further increased in either
groups treated with t-PA in combination with gpIIa/IIIb
inhibitors (tAB: 42% and tEF: 46% vs. the AB and EF
groups, respectively, p < 0.05).
Changes in venular permeability
Before ischemia no detectable fluorescent dextran leakage
was observed in all the groups. In the I/R and tPA groups
a significant increase in permeability was observed in
postcapillary and collecting venules during reperfusion
(baseline: 0.09 ± 0.01 normalized grey levels, p < 0.05,
Fig. 3). The treatment with abiciximab and eptifibatide
significantly attenuated the I/R-induced increase in per-
meability from venules 30 min after reperfusion. In AB
and EF groups a slight increase in permeability was ob-
served from 20–30 min after reperfusion when comparedBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/10
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with tEF and tAB groups (tAB -25% and tEF: -57% vs. the
ABI and EF groups, respectively, p < 0.05)
Changes in platelet and leukocyte adhesion on microves-
sels
In the I/R and tPA group the number of platelets adhering
to arterioles or venules and the number of leukocytes ad-
hering to the postcapillary venules increased significantly
in comparison with baseline values (Figs. 4,5).
t-PA had no protective effect on the number of adhering
platelets in postischemic arterioles and venules. On the
contrary t-PA combined with gpIIa/IIIb inhibitors de-
creased the number of platelets adhering to arterioles and
venules. Concomitantly, the number of leukocytes adher-
ing to the postcapillary venules decreased significantly
compared with I/R group (Figs. 4,5).
The number of leukocytes adhering to the venular wall de-
creased significantly by the end of reperfusion (Fig. 5)
with abiciximab or eptifibatide alone (AB: -42% and EF: -
46% vs. the I/R group, p < 0.05). With abiciximab and ep-
tifibatide there was a significant reduction in platelet ad-
hesion in microvessels (AB: -72 and EF:-74% p < 0.01 vs.
the I/R group). In the AB and EF groups the leukocyte ad-
hesion to venules was -46 and -50% in comparison with
Figure 1
Changes of diameter of arterioles at baseline and during reperfusion in the group treated with saline (I/R) and those treated
with abiciximab (AB), eptifibatide (EF), t-PA (tPA) and abiciximab plus t-PA (tAB) or eptifibatide plus t-PA (tEF), respectively.
See text for details. Values are means ± SD, n = 35 experimental observations for each entry, *p < 0.05 I/R-tPA vs. baseline; ° p
< 0.05 AB-EF-tAB-tEF vs. I/R and tPA; ** p < 0.05 tAB and tEF vs.AB and EF.
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the I/R group, respectively (p < 0.001) (Fig. 5). However,
the number of leukocytes adhering on postcapillary
venules was significantly different when compared with
the tEF and tAB groups (tAB: -37% and tEF-26% vs. the AB
and EF groups, respectively, p < 0.05).
Changes in capillary perfusion
In I/R group PCL decreased significantly when compared
with baseline (baseline: 9,130 ± 430 µm, p < 0.05, Fig. 6.
In Fig. 7 and 8 we reported the photographic sequence of
a hamster cheek pouch microcirculation during baseline,
30 min of ischemia, 10 min and 30 min of reperfusion.
The no reflow phenomenon is evident during reperfusion
as shown by the lack of capillary perfusion at 10 and 30
min from reperfusion. t-PA had no effect on capillary per-
fusion (PCL: 58 ± 5% of baseline, 10,080 ± 400 µm) while
combination of t-PA with abiciximab and eptifibatide de-
termined no alteration in capillary perfusion compared
with the baseline (9980 ± 350 µm, Fig. 6). PCL increased
significantly in comparison with the I/R group, whereas it
was slightly but significantly reduced in comparison with
the baseline (baseline: AB: 8,950 ± 780 µm; EF: 9,780 ±
540 µm) (Fig. 6). In the AB and EF groups postischemic
perfusion in the microcirculation showed a biphasic in-
crease because within 5–10 min after the onset of reper-
fusion, PCL was 70 and 65% and 85 and 87% after 30 min
of reperfusion, vs. the baseline (10,500 ± 500 µm, p <
0.001). In Fig. 7 and 8 we reported the photographic se-
quence of hamster cheek pouch treated with abiciximab.
The capillary perfusion recovered within 10 min after pos-
tischemic reperfusion and after 30 min there was not a
complete capillary perfusion.
PCL increased significantly in the groups treated with t-PA
combined with gpIIa/IIIb inhibitors in comparison with
the AB and EF groups (tAB: 26 and 15% and tEF: 31 and
13% within 15 and 30 min of reperfusion vs. the AB and
EF groups, respectively, p < 0.05). Interestingly, we did not
Figure 2
Changes of arteriolar RBC velocity at baseline and during reperfusion in the group treated with saline (I/R) and those treated
with abiciximab (AB), eptifibatide (EF), t-PA (tPA) and abiciximab plus t-PA (tAB) or eptifibatide plus t-PA (tEF), respectively.
See text for details. Values are means ± SD, n = 20 experimental observations for each entry, *p < 0.05 I/R-tPA vs. baseline; °p
< 0.05 AB, EF, tAB, and tEF vs. I/R and tPA; ** p < 0.05 tAB abd tEF vs.AB and EF.
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observed the postischemic biphasic response in blood
flow as in AB and EF groups but microvascular perfusion
was restored to the preclamping level immediately after
the period of ischemia.
Discussion
Our data demonstrated that the inhibition of platelet ag-
gregation is a crucial event in I/R injury in microvessels as
shown by the effects derived from the treatment with
abicixmab or eptifibatide in the hamster cheek pouch mi-
crocirculation. These drugs reduced platelet aggregation in
arterioles and venules, as well as leukocyte adhesion to
endothelial cells of venules and leukocyte-platelet interac-
tions in microvessels. Although microvascular perfusion
was maintained after 30 min of reperfusion the restora-
tion of blood flow was only within 5–10 min after pos-
tischemic reperfusion.
t-PA combined with abcixmab or eptifibatide-mediated
inhibition of platelet aggregation enhanced and speeded
the restoration of the microvascular perfusion by protect-
ing the endothelial barrier as shown by the decrease in
venular permeability and the increase in arteriolar diame-
ter. The results obtained in this model indicate that there
was still a significant efficacy against microcirculatory dis-
turbances after gpIIa/IIIb inhibitors alone with respect to
their combination with t-PA. This suggest that the in-
creased levels of platelet activation and fibrinolysis are in-
volved more importantly than other factors in I/R injury.
The early recovery of blood flow at the beginning of reper-
fusion may be protective for reducing cellular endothelial
cell injuries.
Previously, we have reported that platelet adhesion was
not confined to postcapillary venules, but was also ob-
served in arterioles of the hamster cheek pouch microcir-
culation during I/R [4]. The decreased perfusion observed
in the capillary network at the beginning of reperfusion
might be related to the increased level of platelet reactivity
in the arterioles during the period of ischemia. Protein ki-
nase C (PKC) is sensitive to oxidation and could be upreg-
ulated during oxidative stress caused by ischemia. It was
shown that many proaggregatory stimuli, such as oxida-
tive stress, have activated PKC involved in the platelet ac-
Figure 3
The permeability (normalized to baseline) during reperfusion in the group treated with saline (I/R) and those treated with
abiciximab (AB), eptifibatide (EF), t-PA (tPA) and abiciximab plus t-PA (tAB) or eptifibatide plus t-PA (tEF), respectively. See
text for details. Values are means ± SD. *p < 0.05 AB, EF, tAB and tEF vs. I/R and t-PA; ° p < 0.05 tAB and tEF vs.AB and EF.
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tivation [21]. The increase in the oxidative stress at the
onset of reperfusion could lead to an increase in P-selectin
expression on the endothelial surface thus increasing
platelet and leukocyte adhesion to microvessels [22,23].
In particular, endothelial cells appear to be very sensitive
to an enhanced level of platelet activation after oxygen
free radicals or cytokine exposure following ischemic oc-
clusion [12]. Inflammatory markers, such as interleukin-6
and tumor necrosis factor-α , measured in serum samples
obtained from 160 patients during angioplasty, decreased
significantly in the first hours after angioplasty following
administration of abciximab. It was hypothesized that
some of the decreased mortality associated with the use of
this agent may be related to an anti-inflammatory effect
exerted by abiciximab [9]. However, measurement of rou-
tine enzymes following early myocardial infarction did
not reveal any early benefit provided by abiciximab [11].
In the microcirculation of hamsters after platelet aggrega-
tion inhibition we did not observe arterial vasoconstric-
tion or significant decreases in RBC velocity after I/R but
an increase in permeability was observed during reper-
fusion thus indicating an impairment of the endothelial
barrier.
It is possible that platelets contributed in part to the delay
in reperfusion through a release of vasoconstrictor sub-
stances, thus causing local perfusion deficiencies of the
microcirculation with occlusion of the vascular lumen
and alterations in the properties of the endothelial barrier
[4,24].
Platelets in the arterial circulation are exposed to very high
shear stress at the beginning of reperfusion. The shear-in-
duced platelet aggregation is enhanced in plasma in the
presence of acute myocardial infarction, apparently as a
result of increased concentration of von Willebrand factor
(vWF) [15]. Under such conditions the time for contact
with damaged vessels is very limited, and it is surprising
that high shear stress favors interaction of platelets with
the subendothelium. Interestingly, after a first peak of ad-
hesion, there is a rapid decrease in the number of adher-
Figure 4
Number of adherent platelets/mm2 of vessel surface at baseline and during reperfusion in the group treated with saline (I/R)
and those treated with abiciximab (AB), eptifibatide (EF), t-PA (tPA) and abiciximab plus t-PA (tAB) or eptifibatide plus t-PA
(tEF), respectively. See text for details. Values are means ± SD, n = 35 experimental observations for each entry, *p < 0.05 vs.
baseline; °p < 0.05 vs. I/R and tPA.
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ent platelets, suggesting that the endothelial surface
becomes less adhesive with time, possibly because vWF or
other factors are progressively washed away [16]. This
phenomenon may help to explain the delay of microvas-
cular perfusion and the reocclusion of some microvessels
at the end of the period of reperfusion, as observed after
treatment with abicixmab or eptifibatide.
Our data show that the protective effects derived from ab-
ciximab or eptifibatide after reperfusion are primarily re-
lated to inhibition of platelet aggregation while other
possibilities contributing to the improvement of I/R inju-
ry, may be related to the effect on platelet adhesion and
platelet-leukocyte adhesion on the endothelial cells of the
venular vessel wall. However, our data showed that the
protection with gpIIa/IIIb was not complete thus showing
a crucial role for t-PA. Interestingly, gpIIb/IIIa Mabs cross-
reacts with the leukocyte integrin Mac-1 receptor on acti-
vated monocytes and macrophages and blocks adhesion
to fibrinogen and ICAM-1 [25], which has also been im-
plicated in the leukocyte recruitment associated with I/R
[26].
Our observations might highlight that platelets appear to
have a central role in thrombosis in I/R injury suggesting
that platelet-dependent processes in I/R injury may signif-
icantly affect the fibrinolytic processes. Interestingly, re-
cent data show a greater tendency of fibrinolytic
inhibition in sepsis in non-leukopenic patients. Further-
more, in shock conditions, levels of t-PA inhibition were
high in both the non-leukopenic and leukopenic groups
[27].
In our model of I/R it appears that although abiciximab or
eptifibatide restored blood flow only abcixmab or eptifi-
batide in combination with t-PA caused a significant in-
crease in diameter of arterioles and recovered complete
microvascular perfusion at the beginning of reperfusion
thus indicating that even relatively mild forms of damage
may be accompanied by local perfusion deficiencies of the
microcirculation and alterations of the endothelial barri-
er. In agreement with our data in patients treated with ep-
tifibatide, with simultaneous accelerated thrombolyis, it
was shown that there was more reperfusion and a shorter
duration of ischemia as shown by the shorter time to
steady state ST-segment recovery [19]. Campbell et al. pro-
Figure 5
Number of adherent leukocytes/100 µm venules at baseline and during reperfusion in the group treated with saline (I/R) and
those treated with abiciximab (AB), eptifibatide (EF), t-PA (tPA) and abiciximab plus t-PA (tAB) or eptifibatide plus t-PA (tEF),
respectively See text for details. Values are means ± SD, n = 25 experimental observations for each entry, *p < 0.001 I/R-tPA
vs. baseline; °p < 0.05 AB, EF, tAB, and tEF vs. I/R; ** p < 0.05 tAB and tEF vs.AB and EF.
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vided evidence that abciximab is a potent and effective
cardioprotective agent, thus suggesting an inhibition of
leukocyte-endothelial cell interactions in order to preserve
cardiac contractile function and coronary perfusion in an
isolated perfused rat heart model of I/R [28].
t-PA might play a role in maintaining microvascular pat-
ency at the beginning of reperfusion by protecting the an-
tithrombogenic characteristics of the vascular
endothelium. In ischemia the impairment of endothelial
cell integrity might predominate, leading to impaired syn-
thesis and/or the release of endothelial substances such as
t-PA. Plasma t-PA is more strictly dependent on endothe-
lial cell function and a better indicator of endothelial via-
bility. Furthermore, the protection afforded by t-PA
against the increase in microvascular permeability might
be related to the reduction of O2
-- due to the protective ef-
fects of t-PA on the endothelium [29]. Upon activation
and aggregation, platelets generate oxygen radicals that
Figure 6
Changes (%) of perfused capillary length (PCL) at baseline and during reperfusion. in the group treated with saline (I/R) and
those treated with t-PA (tPA), abiciximab, (AB), eptifibatide (EF), t-PA and t-PA plus abiciximab (tEF) or eptifibatide (tEF),
respectively. See text for details. Values are means ± SD; *p < 0.001 I/R, tPA, AB, and EF vs. baseline; °p < 0.05 AB, EF, tAB, and
tEF vs. I/R and t-PA; ** p < 0.05 tAB and tEF vs.AB and EF.
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could cause vasoconstriction and occlusion of the arteri-
oles.
In our model t-PA alone did not exert any protection at 30
min of reperfusion and these results are consistent with
data showing that reperfusion treatment by thrombolysis
reduces mortality in patients undergoing percutaneous
coronary intervention, but its efficacy is limited by the oc-
currence of thrombotic reocclusion after reperfusion [11],
thus suggesting that platelets serve the major role in he-
mostasis in arterioles during reperfusion in I/R injury. In
a first systematic evaluation of eptifibatide combined with
low dose t-PA in acute myocardial infarction, Brener et al.
showed that this therapy is superior to standard dose t-PA
alone in achieving reperfusion of the infarct-related artery
60 min after initiation of therapy [13].
Recent data show that t-PA inhibits superoxide anion pro-
duction in human neutrophils in vitro and decreases mor-
tality in patients with acute myocardial infarction [30].
Previously, we showed that leukocytes have a secondary
influence on the fibrinolytic system after 30 min of
ischemia and 30 min of reperfusion while the no reflow
phenomenon during 60 min of ischemia followed by 60
Figure 7
A sequence of photographs documenting I/R-induced injury in the microcirculation of a control hamster in the baseline condi-
tion (a), within 30 min of ischemia (b), 10 min (c) and 30 min (d) of reperfusion. Postischemic microvascular perfusion stopped
in many microvessels and blood flow decreased significantly during reperfusion with the evidence of the no-reflow phenome-
non.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/10
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min of reperfusion appears to be modulated by t-PA in
leukopenic hamsters [20]. In agreement with these data, it
was shown that the percentage stenosis in the coronary ar-
teries measured by coronary angiography was negatively
correlated with t-PA activity that fluctuates because t-PA
levels are different according to the ischemic conditions
[31].
Therefore, it is possible that the protective effects of t-PA
might determine an inhibition of the vasoconstriction
and microthrombus formation in arterioles in combina-
tion with the inhibitors of platelet aggregation, thus al-
lowing an increase in capillary perfusion. The restoration
of blood flow could be essential in the mechanism of pro-
tection, thus determining oxygen delivery to the tissue
and permitting the extraction of by-products of cellular
metabolism during reperfusion. The beneficial effects of t-
PA might also derive from a more marked reduction of
leukocyte and platelet adhesion via the inhibition of oxy-
gen free radical formation.
Study limitations
Although we have demonstrated a role for platelets in the
response to ischemia/reperfusion, there are issues that
need to be addressed by future studies. In particular, we
do not know the extent of damage to the endothelial cells
of the microvessels. For instance, evidence for endothelial
barrier swelling or free radical injury to the tissue could be
obtained by histological study of the tissue following
reperfusion; however, such measurements were beyond
the scope of the present study.
Conclusions
We demonstrated that the inhibition of platelet aggrega-
tion is crucial in I/R injury as shown by the treatment with
abicixmab or eptifibatide that decreased significantly, not
only platelet aggregation in both arterioles and venules,
but also leukocyte adhesion in venules in the hamster
cheek pouch microcirculation. We have shown that the ef-
fects derived from abiciximab or eptifibatide on platelet
reactivity involve leukocyte adhesion to endothelial cells
of venular vessel walls. However, only the abicixmab or
eptifibatide-induced inhibition of platelet aggregation in
conjunction with t-PA speeded up the restoration of
blood flow. Likewise t-PA decreased the levels of vasocon-
striction, abolished the increase in permeability, and in-
creased RBC velocity in the microvessels, thus indicating
that even mild forms of platelet or endothelial cell activa-
tion may be accompanied by local perfusion deficiencies
of the perfusion and alterations in the properties of the
endothelial barrier.
Materials
Male Syrian hamsters (80–100 g Charles River, Calco, Ita-
ly) were used. Hamsters were anesthetized (Nembutal, 5
mg/100 g body wt., i.p.) and tracheotomized. The right ca-
rotid artery and femoral vein were cannulated to measure
blood pressure and to administer additional anesthesia
and drugs, respectively. Animal handling and care fol-
lowed the procedures outlined in the Guide for the Care
and Use of the Laboratories of the Italian Research Coun-
cil.
Experimental groups
In pilot studies we used different doses of abciximab or
eptifibatide. Abiciximab was injected i.v. at 6.5 µg/kg and
eptifibatide at 6 µg/kg because half dosage caused an in-
crease in permeability and leukocyte adhesion on post-
capillary venules. We used six groups: the control (I/R) (n
= 5) group received an intravenous infusion of saline; the
second group (tPA, n = 5) was treated with t-PA (human
rtPA, Sigma Chemical, St. Louis, MO, USA) (50 µg/100 g/
0.7 ml intravenous infusion); the third group (AB, n = 5)
was treated with abiciximab (0.65 µg/100 g infused intra-
venously); the fourth group (EF, n = 5) was treated with
eptifibatide (0.6 µg/100 g infused intravenously); the fifth
group (tAB, n = 6) was treated with t-PA plus abciximab
(50 plus 0.6 µg/100 g intravenous infusion); the sixth
group (tEF, n = 6) was treated with t-PA plus eptifibatide
(50 µg plus 0.65 µg/100 g/min infused intravenously). All
the drugs were injected 10 mins before ischemia and
through 30 mins of reperfusion by using a micropump
The cheek pouch was surgically prepared as previously re-
ported [4,20]. The cheek pouch was gently everted and
fixed to a special platform on the microscope stage. Then
a thin black blade was inserted through a small incision
between the upper and lower layers of the pouch. The
cheek pouch was superfused with a 36 ± 0.5 °C Ringer's
solution (4 ml/min), with 5% CO2 in 95% N2 adjusted to
pH 7.35. Atraumatic microvascular clips were placed on
the proximal part of the cheek pouch to achieve complete
ischemia for 30 min. The clamp was then removed and
the microcirculation was observed for 30 mins during
reperfusion.
Observations were made with a fluorescence microscope
(Orthoplan, Leica Microsystem GmbH, Wetzlar, Germa-
ny) and a filter block (Ploempak, Leica Germany) fitted
with a long working distance objective (× 4, na 0.14; × 20,
na 0.25) and × 10 eyepiece. Epi-illumination was provided
by a xenon 150-W lamp using the appropriate filters for
fluorescein isothiocyanate, bound to dextran (MW
150,000; Sigma Chemical, St. Louis, MO, USA; 50 mg/
100 g b. wt., intravenously injected as 5 % W/V solution
in 5 min), for acridine red and a heat filter. The area of in-
terest was televised with a COHU 5253 SIT (COHU Inc.
San Diego CA, USA) low light level camera, and observed
on a Sony PVM 122 CE monitor. Video images were vide-
otaped and microvascular measurements were made off-BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/10
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line by a computer-assisted imaging software system (MIP
Image, CNR, Institute Clin. Physiology, Pisa, Italy).
Measurements of microvascular parameters
Animals in all the groups received an intravenous injec-
tion of acridine red (1 mg/100 g) to visualize the leuko-
cytes and platelets at baseline and after reperfusion. The
number of adherent leukocytes was expressed as the
number/100 µm length of venule (diameters: 16 ± 8 µm,
length > 250 µm). The number of adherent platelets was
expressed as number/mm2 of vessel surface (diameters:
16 ± 8 µm). In each animal 5 arterioles and 5 venules were
recorded on videotape.
PCL, defined as the total length of capillary segments that
have at least one RBC passing through them in a 30 s pe-
riod, was analyzed from four to six different microscopic
fields. Microvessel diameters were measured by an image
shearing system (Digital Image Shearing Monitor Mod
907, IPM). Red blood cell (RBC) velocity was determined
using dual slit cross correlation (velocity tracker Mod 102
B, IPM, San Diego, CA, USA). The measured centerline ve-
locity was corrected according to vessel size to obtain the
mean RBC velocity.
Figure 8
A sequence of photographs documenting I/R-induced injury in the microcirculation of a hamster treated with abciximab, in the
baseline conditions (a), within 30 min of ischemia (b), 10 min (c) and 30 min (d) of reperfusion. Postischemic capillary perfusion
increased significantly within 10 or 30 min of reperfusion even if there was not complete recovery.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/10
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To quantify the permeability of the venular wall, fluores-
cence intensity in the perivascular space was reported as
normalized to baseline grey levels: NGL = (I - Ir)/Ir, where
I is the average baseline grey level and Ir is the same pa-
rameter after reperfusion [4]. Grey levels, ranging from 0
to 255, were determined by the MIP Image program. The
size of the window used to measure average fluorescence
intensity was set at 50 µm long and 50 µm wide.
Mean arterial blood pressure (MAP) (Viggo-Spectramed
P10E2 transducer, Oxnard, CA, USA) and heart rate (HR)
were measured by a Gould Windograf recorder (Mod. 13-
6615-10S, Gould Inc., Ohio, USA).
All reported values are means ± SD. Differences were test-
ed by paired and unpaired t-test. For analysis between
groups, the Kruskal-Wallis test was used, followed by the
Mann-Whitney U test. Differences were considered signif-
icant at p < 0.05.
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